吉非替尼在中国患者非小细胞肺癌靶向治疗中的作用。
Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.
作者信息
Li Meng-Jiao, He Qing, Li Mei, Luo Feng, Guan Yong-Song
机构信息
Department of Oncology, Center of Oncology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
出版信息
Onco Targets Ther. 2016 Mar 9;9:1291-302. doi: 10.2147/OTT.S80635. eCollection 2016.
Abstract
Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Conventional treatment options have limited efficacy because most cases are in the advanced stage at the time of diagnosis. In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown its good antitumor activities in treating NSCLC in a number of studies. This paper reviews its role in the targeted treatment of NSCLC in Chinese patients.
摘要
非小细胞肺癌（NSCLC）是最常见的肺癌类型。由于大多数病例在诊断时已处于晚期，传统治疗方案的疗效有限。近年来，表皮生长因子受体酪氨酸激酶抑制剂吉非替尼在多项研究中已显示出其在治疗非小细胞肺癌方面良好的抗肿瘤活性。本文综述了其在中国患者非小细胞肺癌靶向治疗中的作用。
相似文献
1
Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.吉非替尼在中国患者非小细胞肺癌靶向治疗中的作用。
Onco Targets Ther. 2016 Mar 9;9:1291-302. doi: 10.2147/OTT.S80635. eCollection 2016.
2
Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.非小细胞肺癌的生物靶向治疗：聚焦于表皮生长因子受体
Clin Lung Cancer. 2003 Sep;5 Suppl 1:S11-7. doi: 10.3816/clc.2003.s.010.
3
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).在非小细胞肺癌（NSCLC）中使用吉非替尼（易瑞沙）“靶向”表皮生长因子受体酪氨酸激酶
Semin Cancer Biol. 2004 Feb;14(1):33-40. doi: 10.1016/j.semcancer.2003.11.005.
4
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.表皮生长因子受体（EGFR）酪氨酸激酶抑制剂吉非替尼（ZD1839，易瑞沙）在非小细胞肺癌细胞系中的抗肿瘤活性与基因拷贝数和EGFR突变相关，但与EGFR蛋白水平无关。
Clin Cancer Res. 2006 Dec 1;12(23):7117-25. doi: 10.1158/1078-0432.CCR-06-0760.
5
Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.扶正抗癌汤联合吉非替尼治疗表皮生长因子受体突变的晚期非小细胞肺癌患者：一项随机对照试验的研究方案
Trials. 2015 Apr 10;16:146. doi: 10.1186/s13063-015-0685-2.
6
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.75 岁或以上携带表皮生长因子受体突变的晚期非小细胞肺癌患者的一线吉非替尼治疗：NEJ 003 研究。
J Thorac Oncol. 2012 Sep;7(9):1417-22. doi: 10.1097/JTO.0b013e318260de8b.
7
Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂联合化疗治疗非小细胞肺癌：吉非替尼存在时携带敏感 EGFR 突变的细胞的化疗耐药性。
Lung Cancer. 2013 Nov;82(2):305-12. doi: 10.1016/j.lungcan.2013.08.028. Epub 2013 Sep 8.
8
Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib.中国患者晚期非小细胞肺癌的治疗：聚焦于埃克替尼。
Onco Targets Ther. 2014 May 16;7:761-70. doi: 10.2147/OTT.S49233. eCollection 2014.
9
Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.通过五个基本要素增强肺癌治疗的策略：吸入给药、纳米技术、肿瘤受体靶向、化学疗法和基因疗法。
Theranostics. 2019 Oct 22;9(26):8362-8376. doi: 10.7150/thno.39816. eCollection 2019.
10
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
引用本文的文献
1
The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.ERBB4 突变在免疫检查点抑制剂治疗晚期非小细胞肺癌中的预后作用。
Mol Med. 2021 Oct 7;27(1):126. doi: 10.1186/s10020-021-00387-z.
2
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring mutations: subgroup analysis of the LUX-Lung 6 trial.阿法替尼对比吉西他滨/顺铂用于一线治疗携带特定突变的中国晚期非小细胞肺癌患者：LUX-Lung 6试验的亚组分析
Onco Targets Ther. 2018 Nov 30;11:8575-8587. doi: 10.2147/OTT.S160358. eCollection 2018.
3
Adiponectin inhibits migration and invasion by reversing epithelial‑mesenchymal transition in non‑small cell lung carcinoma.脂联素通过逆转非小细胞肺癌中的上皮-间质转化抑制迁移和侵袭。
Oncol Rep. 2018 Sep;40(3):1330-1338. doi: 10.3892/or.2018.6523. Epub 2018 Jun 25.
4
The Efficacy of Oil Emulsion Injection as Adjunctive Therapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.注射用榄香烯乳作为晚期非小细胞肺癌辅助治疗的疗效：一项荟萃分析
Evid Based Complement Alternat Med. 2016;2016:5928562. doi: 10.1155/2016/5928562. Epub 2016 Dec 6.
5
The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China.表皮生长因子受体酪氨酸激酶抑制剂作为表皮生长因子受体野生型非小细胞肺癌的二线治疗：一项在中国的真实世界研究。
Onco Targets Ther. 2016 Oct 20;9:6479-6484. doi: 10.2147/OTT.S119341. eCollection 2016.
6
Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer.吉非替尼与韩方草药联合治疗可能是非小细胞肺癌患者的一个有益选择。
J Pharmacopuncture. 2016 Sep;19(3):259-263. doi: 10.3831/KPI.2016.19.028.
本文引用的文献
1
Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.表皮生长因子受体单克隆抗体在非小细胞肺癌治疗中的作用
Curr Cancer Drug Targets. 2015;15(9):792-802. doi: 10.2174/156800961509151110143001.
2
Study of the methylation patterns of the EGFR gene promoter in non-small cell lung cancer.非小细胞肺癌中表皮生长因子受体（EGFR）基因启动子甲基化模式的研究
Genet Mol Res. 2015 Aug 19;14(3):9813-20. doi: 10.4238/2015.August.19.14.
3
Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors.表皮生长因子受体（EGFR）基因突变与表皮生长因子受体酪氨酸激酶抑制剂时代的非小细胞肺癌放疗
Future Oncol. 2015;11(16):2329-42. doi: 10.2217/fon.15.156.
4
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.吉非替尼联合化疗对比安慰剂联合化疗用于一线吉非替尼治疗后进展的 EGFR 突变阳性非小细胞肺癌（IMPRESS）：一项 3 期随机试验。
Lancet Oncol. 2015 Aug;16(8):990-8. doi: 10.1016/S1470-2045(15)00121-7. Epub 2015 Jul 6.
5
Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature.晚期肺腺癌患者弥漫性间质性肺病后再次给予吉非替尼治疗：一例病例报告及文献复习
Oncol Lett. 2015 May;9(5):2419-2421. doi: 10.3892/ol.2015.3026. Epub 2015 Mar 11.
6
Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors.阿法替尼与西妥昔单抗联合用于对表皮生长因子受体（EGFR）抑制剂耐药的EGFR突变型非小细胞肺癌患者。
Onco Targets Ther. 2015 May 19;8:1137-42. doi: 10.2147/OTT.S75388. eCollection 2015.
7
Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.立体定向放射外科联合吉非替尼治疗非小细胞肺癌脑转移患者可提高生存率：台湾的一项全国性研究
Radiat Oncol. 2015 Jun 6;10:127. doi: 10.1186/s13014-015-0431-7.
8
Advances on EGFR mutation for lung cancer.肺癌中 EGFR 突变的研究进展。
Transl Lung Cancer Res. 2012 Mar;1(1):5-13. doi: 10.3978/j.issn.2218-6751.2011.12.01.
9
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].吉非替尼与紫杉醇/卡铂治疗晚期肺腺癌患者的疗效对比
Zhonghua Yi Xue Za Zhi. 2014 Aug 13;94(30):2337-41.
10
Report of cancer incidence and mortality in China, 2010.中国癌症发病率和死亡率报告，2010 年。
Ann Transl Med. 2014 Jul;2(7):61. doi: 10.3978/j.issn.2305-5839.2014.04.05.
Zotero 插件